Phoenix Molecular Designs CEO and Founder, Dr. Sandra E. Dunn, Awarded a Place on the Forbes 50 over 50 Vision List for Her Life's Work in Cancer Research
/Aug. 12 2021
SAN DIEGO, California - VANCOUVER, British Columbia - August 12, 2020, Forbes announced today that Dr. Sandra Dunn, CEO and Founder of Phoenix Molecular Designs (PhoenixMD), has been awarded a coveted place on its inaugural 50 Over 50 Vision list. The list highlights the exceptional women who are shaping the future of science, technology and art. These 50 recipients were selected as visionaries who are leaving a lasting impression on society and culture.
In 2012, Dr. Dunn founded Phoenix Molecular Designs, where she identified a unique approach to treating triple-negative breast cancer developing novel drugs around kinases, specifically p90 ribosomal S6 kinases (RSK). PhoenixMD is one of the few female-led biotechnology companies aimed at eradicating breast cancer. Sandra is breaking the mold of biotechnology companies, inspiring women, encouraging diversity and putting patient care first.
She is a leading figure in the breast cancer biotechnology industry with 28 years of breast cancer R&D experience. Personal experiences with the disease in her family motivate her to commit her life to empower and improve the lives of thousands of women battling breast cancer globally.
"It is a great honor for me to be named one of the top 50 women on the Forbes first 50 over 50 Vision list. I am grateful to be included with this group of exceptional women who have given and accomplished so much in shaping the future of science, art and technology," said Dr. Dunn. "It is truly my life's work to bring an end to metastatic breast cancer. To be acknowledged in this way makes me even more determined to see my company, PhoenixMD, develop highly successful therapies which result in a brighter future for the patients we serve."
Sandra has led multinational oncology research projects to advance the development of novel cancer therapeutics and has built amazing teams to achieve these goals. For three decades, she has raised millions of dollars to fund cancer research and served on the Susan Komen Foundation, Canadian Breast Cancer Foundation, and the Department of Defense (DOD) Breast Cancer Research Program (USA). She was the youngest member of the DOD Breast Cancer Research Program in the early 1990s and was recognized early on for her commitment to the field as a postdoctoral fellow at the National Institutes of Health.
The Forbes 50 Over 50 Vision List was created in partnership with Mika Brzezinski's "Know Your Value" campaign. These much sought-after lists are dedicated to highlighting the exceptional achievements of women over the age of 50 who have gained significant success later in their careers, often overcoming formidable odds or barriers.
About Phoenix Molecular Designs
PhoenixMD is a privately-held clinical-stage biopharmaceutical company designing precise cancer therapeutics and companion diagnostics by targeting kinases, a class of highly druggable enzymes to treat a wide range of oncology indications. PhoenixMD is focused on developing first-in-class inhibitors against RSK, an important drug target for cancer, heart disease, and inflammation. The company's leadership team boasts previous expertise in developing FDA-approved and marketed drugs in oncology. Due to PhoenixMD's emerging leadership in kinase inhibition, the company has entered into partnerships with multiple government and academic research institutions, including the National Cancer Institute, MD Anderson Cancer Center, Kyushu University (Japan), University of Tuebingen (Germany), as well as multiple patient advocacy groups including the Susan G. Komen Foundation in San Diego. PhoenixMD has clinical headquarters in San Diego, CA, and preclinical operations in Vancouver, BC. For more information, visit phoenixmd.ca
###
Contact
Morgan Consaul
Marketing and Communications Manager
Phoenix Molecular Designs
mconsaul@phoenixmd.ca
604 762-6443